The Advanced Industries Accelerator (AIA) Program announced that 22 Colorado companies and five researchers were approved to receive Proof of Concept and Early Stage Capital and Retention grants for a total of $6,350,918 million in funding. GelSana Therapeutics, Inc. is one of the 22 companies that will receive an award. Proof-of-Concept grants are open to certified Colorado research universities and federal labs located in Colorado for pre-commercialization research and commercialization preparation. Early Stage Capital and Retention grants fund early stage companies commercializing innovative technologies to create viable products that meet a market need and can be created or manufactured in Colorado and exported globally. The AIA Program received 106 applications this grant cycle. Applications were reviewed in a multi-stage review process by committees of business, technical and financial experts in the seven advanced industries. Final recommendations were approved by the Economic Development Commission on November 18, 2021.